Ulipristal(159811-51-5)

Ulinastatin acetate is a new type of oral emergency contraceptives, and is the active chemical component of Ella, a new generation of emergency contraceptives currently sold in the United States. It can not only be used within 120 hours after unprotected sex in women, but also the efficacy of emergency contraception will not decline with the delay of medication. At the same time, it has good safety and tolerance. Compared with levonorgestrel, the most commonly used emergency contraceptive at present, ulinastatin acetate has wider clinical applicability and has the potential to prevent more unwanted pregnancies. Ulinastatin Acetate was developed by HRA Pharmaceutical Co., Ltd., and was approved by FDA in August 2010. Its trade name is Ella. It is used to prevent pregnancy within 120 hours after unprotected sex or known or suspected contraceptive failure. Ulinastatin acetate is a selective progesterone receptor regulator, which plays an emergency contraceptive role mainly by inhibiting ovulation. Relevant studies have found that when administered near the day of ovulation (the highest chance of pregnancy), ulinastatin acetate can more effectively inhibit ovulation than levonorgestrel, which suggests that ulinastatin acetate may have stronger emergency contraceptive effect.